clinical trial · NCT04649411
Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
Keryx Biopharmaceuticals·phase3·withdrawn
Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Diseaseferric citratestandard of care
brief summary
This study will be conducted to evaluate the safety and tolerability of ferric citrate in pediatric participants with iron deficiency anemia (IDA) associated with non-dialysis dependent chronic kidney disease (NDD-CKD).
started
Jan 1, 2025
primary completion
Jan 1, 2027
completion
Mar 1, 2027
last updated
Nov 20, 2025
official title
A 24-Week, Open-Label, Randomized, 2-Arm Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol